Pinnacle Associates LTD Immuno Gen, Inc. Transaction History

Pinnacle Associates LTD

$6.3 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 19, 2024	SELL	$12.46 - $29.95 $54,375 - $130,701	-4,364 Reduced 0.43%	1,011,792 $30 Million
Q3 2023 Oct 23, 2023	SELL	$14.09 - $19.87 $2.73 Million - $3.85 Million	-193,767 Reduced 16.01%	1,016,156 $16.1 Million
Q2 2023 Jul 26, 2023	SELL	$3.75 - $20.05 $437,085 - $2.34 Million	-116,556 Reduced 8.79%	1,209,923 $22.8 Million
Q1 2023 May 04, 2023	SELL	$3.67 - $4.92 $25,979 - $34,828	-7,079 Reduced 0.53%	1,326,479 $5.09 Million
Q4 2022 Jan 31, 2023	BUY	$4.55 - $6.31 $29,529 - $40,951	6,490 Added 0.49%	1,333,558 $6.61 Million
Q4 2022 Jan 25, 2023	SELL	$4.55 - $6.31 $99,622 - $138,157	-21,895 Reduced 1.62%	1,327,068 $0
Q3 2022 Oct 31, 2022	SELL	$4.48 - $6.47 $186,229 - $268,951	-41,569 Reduced 2.99%	1,348,963 $6.45 Million
Q2 2022 Aug 02, 2022	SELL	$3.15 - $5.76 $44,528 - $81,423	-14,136 Reduced 1.01%	1,390,532 $6.26 Million
Q1 2022 May 05, 2022	BUY	$4.26 - $7.48 $931,278 - $1.64 Million	218,610 Added 18.43%	1,404,668 $6.69 Million
Q4 2021 Feb 02, 2022	BUY	$4.75 - $7.5 $1.54 Million - $2.43 Million	324,176 Added 37.61%	1,186,058 $8.8 Million
Q3 2021 Oct 19, 2021	SELL	$5.02 - $6.59 $149,821 - $196,678	-29,845 Reduced 3.35%	861,882 $4.89 Million
Q2 2021 Aug 02, 2021	BUY	$5.79 - $8.6 $79,143 - $117,553	13,669 Added 1.56%	891,727 $5.88 Million
Q1 2021 May 12, 2021	SELL	$6.5 - $10.53 $632,840 - $1.03 Million	-97,360 Reduced 9.98%	878,058 $7.11 Million
Q4 2020 Jan 26, 2021	SELL	$3.7 - $7.66 $240,548 - $497,999	-65,013 Reduced 6.25%	975,418 $6.29 Million
Q3 2020 Oct 23, 2020	SELL	$3.45 - $4.89 $160,780 - $227,888	-46,603 Reduced 4.29%	1,040,431 $3.75 Million
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $3.65 Million - $5.86 Million	-1,098,005 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$2.12 - $6.8 $367,145 - $1.18 Million	-173,182 Reduced 13.62%	1,098,005 $3.74 Million
Q4 2019 Feb 03, 2020	SELL	$2.25 - $5.8 $195,615 - $504,252	-86,940 Reduced 6.4%	1,271,187 $6.49 Million
Q3 2019 Nov 08, 2019	SELL	$2.22 - $3.39 $181,458 - $277,091	-81,738 Reduced 5.68%	1,358,127 $3.29 Million
Q2 2019 Aug 05, 2019	SELL	$1.8 - $3.3 $301,915 - $553,512	-167,731 Reduced 10.43%	1,439,865 $3.13 Million
Q1 2019 May 10, 2019	BUY	$2.41 - $5.91 $1.68 Million - $4.13 Million	698,820 Added 76.9%	1,607,596 $4.36 Million
Q4 2018 Feb 05, 2019	SELL	$3.94 - $9.7 $131,611 - $324,018	-33,404 Reduced 3.55%	908,776 $4.36 Million
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $1.33 Million - $1.74 Million	-154,757 Reduced 14.11%	942,180 $8.92 Million
Q2 2018 Aug 08, 2018	SELL	$9.52 - $12.15 $1.62 Million - $2.07 Million	-170,570 Reduced 13.46%	1,096,937 $10.7 Million
Q1 2018 May 11, 2018	SELL	$6.7 - $12.95 $366,650 - $708,675	-54,724 Reduced 4.14%	1,267,507 $13.3 Million
Q4 2017 Feb 12, 2018	SELL	$5.07 - $7.92 $732,351 - $1.14 Million	-144,448 Reduced 9.85%	1,322,231 $8.48 Million
Q3 2017 Nov 13, 2017	SELL	$5.4 - $8.47 $275,184 - $431,631	-50,960 Reduced 3.36%	1,466,679 $11.2 Million
Q2 2017 Aug 09, 2017	BUY	N/A	1,517,639	1,517,639 $10.8 Million

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Account